

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

SU-DIPG-XIII

RRID:CVCL_IT41

Type: Cell Line

Proper Citation

RRID:CVCL_IT41

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_IT41

Proper Citation: RRID:CVCL_IT41

Description: Cell line SU-DIPG-XIII is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Diffuse intrinsic pontine glioma

Defining Citation: [PMID:25939062](#), [PMID:26115193](#), [PMID:28823557](#), [PMID:31439867](#), [PMID:33319914](#), [PMID:34078608](#), [PMID:34215733](#), [PMID:34732238](#)

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SU-DIPG-XIII

Synonyms: SU DIPG XIII, SU-DIPGXIII, SU-DIPG-13, DIPG XIII, DIPGXIII, SJHGG054833, Stanford University-Diffuse Intrinsic Pontine Glioma-XIII

Cross References: cancercellines:CVCL_IT41, GEO:GSM4969590, GEO:GSM4969591, GEO:GSM4969592, GEO:GSM4969593, GEO:GSM4969619, GEO:GSM4969628, GEO:GSM4969629, GEO:GSM4969630, GEO:GSM4969657, GEO:GSM5356026, Wikidata:Q54970736

ID: CVCL_IT41

Record Creation Time: 20220427T221612+0000

Record Last Update: 20260905T182515+0000

Ratings and Alerts

No rating or validation information has been found for SU-DIPG-XIII.

No alerts have been found for SU-DIPG-XIII.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Keane L, et al. (2026) Microglia in diffuse midline glioma contribute to extracellular matrix remodelling and cancer cell invasion. *Cell death & disease*, 17(1).

Sharma M, et al. (2024) Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence. *Molecular cancer therapeutics*, 23(1), 24.

Kim H, et al. (2024) MTOR modulation induces selective perturbations in histone methylation which influence the anti-proliferative effects of mTOR inhibitors. *iScience*, 27(3), 109188.

Mota M, et al. (2023) Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas. *Proceedings of the National Academy of Sciences of the United States of America*, 120(18), e2221175120.

Venneti S, et al. (2023) Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. *Cancer discovery*, 13(11), 2370.

Furth N, et al. (2022) H3-K27M-mutant nucleosomes interact with MLL1 to shape the glioma epigenetic landscape. *Cell reports*, 39(7), 110836.

Panditharatna E, et al. (2022) BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma. *Cancer discovery*, 12(12), 2880.

Harpaz N, et al. (2022) Single-cell epigenetic analysis reveals principles of chromatin states in H3.3-K27M gliomas. *Molecular cell*, 82(14), 2696.

Siddaway R, et al. (2022) Splicing is an alternate oncogenic pathway activation mechanism in glioma. *Nature communications*, 13(1), 588.

Tsai JW, et al. (2022) FOXR2 Is an Epigenetically Regulated Pan-Cancer Oncogene That Activates ETS Transcriptional Circuits. *Cancer research*, 82(17), 2980.

Keane L, et al. (2021) Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse midline gliomas. *Neuro-oncology advances*, 3(1), vdab096.

Chung C, et al. (2020) Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. *Cancer cell*, 38(3), 334.

Anastas JN, et al. (2019) Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. *Cancer cell*, 36(5), 528.

Xie Q, et al. (2018) N6-methyladenine DNA Modification in Glioblastoma. *Cell*, 175(5), 1228.